Allakos Inc (NAS:ALLK)
$ 1.3 0.04 (3.17%) Market Cap: 112.57 Mil Enterprise Value: 59.75 Mil PE Ratio: 0 PB Ratio: 1.55 GF Score: 28/100

Allakos Inc. - Special Call Transcript

Mar 24, 2020 / 09:00PM GMT
Release Date Price: $59.12 (+4.42%)
Operator

Greetings and welcome to the Allakos trial initiation and corporate update. (Operator Instructions) As a reminder, this conference is being recorded. I would now like to turn the conference over to our host, Robert Alexander, Chief Financial -- Chief Executive Officer. Thank you. You may begin.

Robert Alexander
Allakos Inc. - CEO & Director

Thank you and I'd like to thank everybody for joining our call.

A reminder that I will be making forward-looking statements. So please refer to our most recent regulatory filings, in particular, our 10-K for a broader discussion of our risk factors.

On Slide 3. In terms of agenda, I will go through an overview and then turn it over to Henrik to go through the clinical trials details, and then at the end, we'll have a Q&A.

Okay. So on Slide 5. In terms of an overview, we recently initiated our Phase III study in eosinophilic gastritis and/or eosinophilic duodenitis. We previously referred to this as EGE, but it's simply a name change to be more precise. We also recently initiated a Phase

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot